FDA
-
-
-
-
-
-
-
Dyne Therapeutics receives orphan drug designation in Japan for DM1 treatment
-
-
-
-
-
-
-
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
-
-
-
-
-
-
-
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
-
-
-
-
-
-
-
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN), PT $66
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Dyne Therapeutics (DYN)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

